TruSight Inherited Disease

TruSight Inherited Disease

TruSight Inherited Disease is a 550-gene panel covering 2.25 Mb of genomic content focused on severe, pediatric onset disorders. It was developed in collaboration with Dr. Stephen Kingsmore, a MedScape 2012 Physician of the Year and a Time Magazine’s Top Ten Medical Breakthroughs of 2012.

Catalog ID(s):
FC-121-0205, TG-141-1005* (Content Set for up to 48 samples, 4 enrichments)
And one or more of the following TruSight Rapid enrichment kits:
FC-140-1101, TG-140-1101* (1 index, 8 samples, 8 enrichments)
FC-140-1102, TG-140-1102* (2 indices, 8 samples, 4 enrichments)
FC-140-1103, TG-140-1103* (4 indices, 16 samples, 4 enrichments)
FC-140-1104, TG-140-1104* (24 indices, 48 samples, 4 enrichments)
FC-140-1105, TG-140-1105* (24 indices, 96 samples, 8 enrichments)
FC-140-1106, TG-140-1106* (96 indices, 288 samples, 24 enrichments)

*TG-labeled consumables include features intended to help customers reduce the frequency of revalidation. They are available only under supply agreement and require customers to provide a binding forecast. TruSight content sets are available for evaluation purposes prior to executing a supply agreement. Contact your account manager for more information.

Order Now Support

Please rotate your device for details

* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.
† Based on 150x mean coverage of targeted content.
Project Recommendations
Species Compatibility Human
Recommended Illumina Instrument* MiSeq NextSeq 500
Recommended Samples per run† 4 (v2 chemistry)
8 (v3 chemistry)		 48 96
Run Mode - Mid Output High Output
Max Recommended Read Length Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp
Recommended Secondary Analysis
  • MiSeq Reporter Enrichment Workflow
  • BWA Enrichment BaseSpace App
  • Isaac Enrichment v2 BaseSpace App
Recommended Down Stream Analysis VariantStudio VariantStudio
Order Now Support
For Research Use Only

Not for use in diagnostic procedures.

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.